A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH), treatment with dapagliflozin is beneficial for ...

A diabetes drug, dapagliflozin, has shown promise in treating fatty liver disease by reducing liver fat and scarring, ...

Telangana: In a raid conducted at the residence of a habitual offender in Hyderabad, the Drugs Control Administration, ...

Dapagliflozin helped people reduce fat levels in their liver and avoid liver scarring that comes with the condition, which ...

Telangana Drug Control Administration seized fake antidiabetic, antihypertensive, and abortion pills worth Rs. 5.21 lakh from ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...

A new study reveals that dapagliflozin, a common diabetes medication, could significantly improve conditions like metabolic ...

Improves fibrosis and steatohepatitis Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad clinical spectrum, ranging from simple steatosis to metabolic ...

Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra), said accompanying editorial authors Leila Haddad, MD, and Sebastián ...